# Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

> **NCT06566807** · PHASE2 · RECRUITING · sponsor: **Huai'an First People's Hospital** · enrollment: 51 (estimated)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Orelabrutinib, obinutuzumab

## Key facts

- **NCT ID:** NCT06566807
- **Lead sponsor:** Huai'an First People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-25
- **Primary completion:** 2026-08-10
- **Final completion:** 2028-08-10
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06566807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06566807, "Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06566807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*